header logo image

Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. – American Depositary Shares (APOP) – The Cerbat Gem

May 3rd, 2017 9:41 am

The Cerbat Gem
Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. - American Depositary Shares (APOP)
The Cerbat Gem
Rodman & Renshaw reissued their buy rating on shares of Cellect Biotechnology Ltd. American Depositary Shares (NASDAQ:APOP) in a research report report published on Tuesday, April 4th. Rodman & Renshaw currently has a $1.00 price objective on ...
Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.Nasdaq

all 2 news articles »

Read the original post:
Rodman & Renshaw Reiterates Buy Rating for Cellect Biotechnology Ltd. - American Depositary Shares (APOP) - The Cerbat Gem

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick